A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3304 participants.

Also called NCT02451137

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,304 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02451137
Other papers using this trial's data
  • Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control Journal of diabetes and its complications, 2021-04 DOI, PubMed 33509703

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02451137. Randomized; no masking; primary purpose treatment. Start 2015-06-16 (actual); primary completion 2018-03-02 (actual). Results posted on 2019-05-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin glargine, 300 U/ml
Intervention (Drug)
Insulin glargine, 100 U/ml
Intervention (Drug)
Insulin detemir
Intervention (Drug)
Background Therapy
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02451137
Content hash
d40862a1c12448434f33d10269308b6181d994d8f0f7fee6ba271e87bd02b0f1